Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JAGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsJaguar Health adjourns annual meeting after Nasdaq discussions, exchanges preferred stock
Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
high
Company adjourned 2026 Annual Meeting from May 22 to June 2 following discussions with Nasdaq staff, will file proxy supplement with additional information before stockholders vote on proposals.
Item 5.07 view on EDGAR → -
high
Nasdaq discussions prompted need for additional disclosure to stockholders regarding certain proxy proposals, though specific issues were not disclosed in the filing.
Item 5.07 view on EDGAR → -
medium
Exchanged 7.96 shares of Series Q Preferred Stock for 54,222 common shares with Streeterville Capital on May 21, increasing common shares outstanding and potentially diluting existing shareholders.
Item 3.02 view on EDGAR → -
medium
Exchange represents small portion of 408 Series Q Preferred shares issued to Streeterville just two days earlier on May 19, suggesting ongoing capital structure adjustments.
Item 3.02 view on EDGAR →
Summary
Jaguar Health called its 2026 Annual Meeting to order on May 22 but immediately adjourned it until June 2 after recent discussions with Nasdaq staff. The exchange requires the company to provide stockholders with additional information about certain proxy proposals before voting proceeds, though the filing does not specify which proposals or what concerns Nasdaq raised.
A proxy supplement will be filed before the reconvened meeting. Separately, the company completed two exchange transactions with Streeterville Capital on May 21, converting 7.96 shares of Series Q Preferred Stock into 54,222 common shares. This follows a May 19 issuance of 408 Series Q Preferred shares to the same investor, indicating active capital structure management with this financing partner.
The exchanges increase common shares outstanding, creating dilution for existing common stockholders. Retail investors should watch for the proxy supplement filing to understand what additional disclosures Nasdaq deemed necessary and whether they materially affect the voting proposals. The ongoing transactions with Streeterville also warrant monitoring, as they suggest the company may be managing near-term capital needs through equity-based restructuring.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
As previously disclosed, on May 19, 2026, Jaguar Health, Inc. (the “Company”) sold and issued to Streeterville Capital, LLC (“Streeterville”) an aggregate of 408 shares of Series Q Perpetual Preferred Stock (the “Series Q Preferred Stock”) in two privately negotiated exchange transactions.
The filing references that on May 19, 2026, just two days before the current exchange, the company had issued 408 shares of Series Q Preferred Stock to Streeterville. The current exchange of 7.96 shares represents a small portion of that recent issuance, suggesting ongoing capital structure adjustments with this investor.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
in light of its recent discussions with the staff of The Nasdaq Stock Market LLC (“Nasdaq”), the Company planned to provide additional information to its stockholders regarding certain proposals
The company has been in discussions with Nasdaq staff that prompted the need for additional disclosure to stockholders. While the 8-K does not specify what issues Nasdaq raised or which proposals require additional information, such discussions typically relate to compliance matters or disclosure adequacy concerns that could affect stockholder voting decisions.
Added in current filing · verify on EDGAR →
The Company will file a supplement to the Proxy Statement (the “Supplement”) to provide aforesaid additional information prior to the reconvened meeting.
The company commits to filing a supplement to its proxy statement before the June 2 reconvened meeting. Stockholders are encouraged to review both the original proxy statement and the forthcoming supplement in their entirety before voting on the proposals at the reconvened meeting.
Event · Item 9.01 — Financial Statements and Exhibits
Jaguar Health executed two Streeterville Exchange Agreements on May 21, 2026, with no details disclosed in the 8-K body.
Added in current filing · verify on EDGAR →
First Streeterville Exchange Agreements, dated May 21, 2026
The company entered into First Streeterville Exchange Agreements on May 21, 2026. The 8-K provides no details about the terms, parties, or purpose of these exchange agreements. Streeterville Capital typically engages in debt or equity restructuring transactions, suggesting this may involve modification of existing securities or obligations.
Added in current filing · verify on EDGAR →
Second Streeterville Exchange Agreements, dated May 21, 2026
The company also entered into Second Streeterville Exchange Agreements on the same date, May 21, 2026. The existence of two separate sets of exchange agreements on the same day suggests multiple tranches or categories of securities being restructured. Without the actual exhibit text, investors cannot assess the financial impact, dilution risk, or strategic rationale.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 23, 2026 · How we verify